6 results
First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotide modifies…
To examine the effects of mono- and combination therapy with linagliptin and empagliflozine on renal hemodynamics
Assess whether: trimetazidine treatment 1) improves LV diastology; 2) improves LV myocardial energy content in HFpEF.
The purpose of this study is to investigate how safe the new compound IMB-1018972 is and how well it is tolerated when it is administered to healthy volunteers. It will also be investigated how quickly and to what extent IMB1018972 is absorbed and…
The main objective of this study is to assess whether in-hospital administration of empagliflozin results in improvement in HF-related outcomes in patients hospitalised for acute heart failure (de novo or decompensated chronic HF) and after initial…
Main objective: to measure the effect of trimetazidine on myocardial external efficiency in asymptomatic MYH7, MYBPC3 or TNNT2 mutation carriers Secondary objectives: to study the effect of trimetazidine on diastolic function, left ventricle and…